Login

AI Research Assistant for Biotech Investors

Analyze clinical trials, compare press releases, and research competitors - all with AI assistance.

Get Started

See What Our AI Can Do

Turn clinical studies and press releases into investment insights. Instantly.

01
๐Ÿ“ก

Unified Data Feed

Search across FDA reviews, clinical trial publications, and press releases simultaneously. Get complete coverage in one place.

Show me all regulatory and clinical updates on ATYR1923 in the past 6 months
๐Ÿ›๏ธ FDA Reviews
๐Ÿงช Clinical Trial Publications
๐Ÿ“ฐ Press Releases
โ†’
โ†’
โ†’
AlterSig AI
โ†’
๐Ÿ“Š
Unified Feed
One search, all sources
02
๐Ÿ“Š

Extract Clinical Data

Extract efficacy data, patient characteristics, and trial outcomes from clinical publications - automatically formatted into clear tables.

Create a table of the efficacy data and baseline patient data from this clinical study
AI Response:

Baseline Patient Characteristics

Characteristic Placebo (n=12) Treatment 1mg (n=8) Treatment 3mg (n=8) Treatment 5mg (n=9)
Age, years 52.5 ยฑ 10.2 54.5 ยฑ 11.3 51.8 ยฑ 11.4 50.8 ยฑ 9.8
Sex, female 7 (58.3%) 4 (50%) 4 (50%) 5 (55.6%)
Disease duration, years 2.9 5.3 4.3 2.9
From PDF to table in seconds
03
๐Ÿ”

Compare Claims vs Evidence

Spot discrepancies between company press releases and peer-reviewed publications. Know what the data actually shows.

Compare the press release and publication
AI Response:

Key Discrepancies Identified

"Clinically meaningful improvements in forced vital capacity (FVC) of 3.3% observed in the 5.0 mg/kg treatment group."

While a 3.3% improvement was reported, this finding did not achieve statistical significance. The publication states improvements were "nonsignificant" and should be considered only as a "trend" requiring further investigation.

Citation: Page 6: "Although the improvements did not achieve statistical significance at the 5 mg/kg dose level..."
Catch overstated claims instantly
04
๐Ÿงฌ

Competitive Intelligence

Identify competing drugs by mechanism of action. Understand the competitive landscape in seconds.

List drugs with similar mechanisms of action for this disease that have been studied in the past 10 years
AI Response:

Drugs with Similar Mechanism of Action (2015-2025)

Nintedanib (OFEV)
Tyrosine kinase inhibitor โ€ข FDA approved for IPF โ€ข Phase 3 completed
Pirfenidone (Esbriet)
Anti-fibrotic agent โ€ข FDA approved โ€ข Multiple Phase 3 trials
Pamrevlumab
Anti-CTGF antibody โ€ข Phase 3 ongoing โ€ข Similar MOA to ATYR1923
+ 7 more compounds analyzed
Know your competition in seconds